Mouse Anti-B4GALNT1 Recombinant Antibody (CBT4705) (V2LY-0625-LY1809)

Name: Mouse Anti-B4GALNT1 Recombinant Antibody (CBT4705)
SKU: V2LY-0625-LY1809
Rating: 5 (1 reviews)

See all B4GALNT1 antibodies

Compare Online Inquiry

Tested Data

Mouse Anti-B4GALNT1 Recombinant Antibody (CBT4705) (V2LY-0625-LY1809) in ELISA

Mouse Anti-B4GALNT1 Recombinant Antibody (CBT4705) (V2LY-0625-LY1809) in WB

Mouse Anti-B4GALNT1 Recombinant Antibody (CBT4705) (V2LY-0625-LY1809) in FC

Mouse Anti-B4GALNT1 Recombinant Antibody (CBT4705) (V2LY-0625-LY1809) in IHC

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBT4705

Application

WB, IHC, FC

Immunogen

Purified recombinant fragment of human B4GALNT1 (AA: 26-225) expressed in E. Coli.

Host Species

Mouse

Specificity

Human

Antibody Isotype

IgG1

Clonality

Monoclonal Antibody

Application Notes

Application	Note
WB	1:500-1:2,000
IHC-P	1:200-1:1,000
FC	1:200-1:400
ELISA	1:10,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS

Preservative

Sodium azide

Concentration

Batch dependent

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

Beta-1,4-N-Acetyl-Galactosaminyltransferase 1

Entrez Gene ID

2583

UniProt ID

Q00973

Function

Involved in the biosynthesis of gangliosides GM2, GD2, GT2 and GA2 from GM3, GD3, GT3 and GA3, respectively.

Biological Process

Carbohydrate metabolic process Source: ProtInc
Ganglioside biosynthetic process Source: UniProtKB
Glycosphingolipid metabolic process Source: Reactome
Lipid glycosylation Source: InterPro
Lipid storage Source: Ensembl
Spermatogenesis Source: Ensembl

Cellular Location

Golgi apparatus membrane

Involvement in disease

Spastic paraplegia 26, autosomal recessive (SPG26): A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG26 is a complicated form characterized by onset in the first 2 decades of life of gait abnormalities due to lower limb spasticity and muscle weakness. Some patients have upper limb involvement. Additional features include intellectual disability, peripheral neuropathy, dysarthria, cerebellar signs, extrapyramidal signs, and cortical atrophy. The disorder is slowly progressive.

Topology

Cytoplasmic: 1-7 aa
Helical: 8-25 aa
Lumenal: 26-533 aa

Jiang, T., Wu, H., Lin, M., Yin, J., Tan, L., Ruan, Y., & Feng, M. (2021). B4GALNT1 promotes progression and metastasis in lung adenocarcinoma through JNK/c-Jun/Slug pathway. Carcinogenesis, 42(4), 621-630.

Jing, S., Deng, Z., Liang, L., & Liang, J. (2020). B4GALNT1 enhances cell proliferation and growth in oral squamous cell carcinoma via p38 and JNK MAPK pathway. Translational Cancer Research, 9(4), 2340-2348.

Yoshida, H., Koodie, L., Jacobsen, K., Hanzawa, K., Miyamoto, Y., & Yamamoto, M. (2020). B4GALNT1 induces angiogenesis, anchorage independence growth and motility, and promotes tumorigenesis in melanoma by induction of ganglioside GM2/GD2. Scientific reports, 10(1), 1-12.

Bhuiyan, R. H., Ohmi, Y., Ohkawa, Y., Zhang, P., Takano, M., Hashimoto, N., ... & Furukawa, K. (2019). Loss of enzyme activity in mutated B4GALNT1 gene products in patients with hereditary spastic paraplegia results in relatively mild neurological disorders: similarity with phenotypes of B4galnt1 knockout mice. Neuroscience, 397, 94-106.

Dad, R., Malik, U., Javed, A., Minassian, B. A., & Hassan, M. J. (2017). Structural annotation of Beta-1, 4-N-acetyl galactosaminyltransferase 1 (B4GALNT1) causing Hereditary Spastic Paraplegia 26. Gene, 626, 258-263.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-B4GALNT1 Recombinant Antibody (CBT4705)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-B4GALNT1 Recombinant Antibody (CBYY-0088) (CAT#: CBMAB-0088-YY)

Mouse Anti-B4GALNT1 Recombinant Antibody (14G2a) (CAT#: CBMAB-G1280-LY)

Mouse Anti-B4GALNT1 Recombinant Antibody (CBLG1-004) (CAT#: CBMAB-G0008-LY)

Mouse Anti-B4GALNT1 Recombinant Antibody (ME361) (CAT#: CBMAB-G1282-LY)

Mouse Anti-B4GALNT1 Recombinant Antibody (1024912) (CAT#: CBMAB-G1281-LY)

Mouse Anti-B4GALNT1 Recombinant Antibody (5F9) (CAT#: CBMAB-A0688-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry